News

VIPC Awards Commonwealth Commercialization Fund Grant to PS Fertility to Advance Fertility Testing

The Virginia Innovation Partnership Corporation (VIPC) today announced that PS-Fertility, Inc. has been awarded a Commonwealth Commercialization Fund (CCF) grant for $75,000. VIPC’s CCF programs have distributed more than $53 million to Virginia-based startups, entrepreneurs, and university-based inventors since 2012 in support of critical early technology testing and market validation efforts. PS Fertility has also previously received funding from VIPC’s Virginia Venture Partners.

 

Each year in the U.S. alone, approximately 7 million couples seek fertility care. Roughly 50% of infertility is due to the male, yet historically the reasons why are largely a mystery and the diagnostic and treatment burdens have fallen disproportionately on the female. PS Fertility, a clinical diagnostic company spun out of the University of Virginia, is changing the way male fertility testing is conducted with their novel discovery that quantifies the levels of fertilization-competent sperm. Equipped with this information, healthcare providers can better advise couples of the likelihood of fertilization and help guide treatment options.

 

“Our patent-pending technology takes fertility testing to a new level beyond just sperm counting and motility measurement. We can assess the ability of a sperm to fertilize an egg, allowing us to uncover meaningful information about male infertility that’s not currently available through conventional testing. This helps provide couples with insight into their personal fertility journey and improve their ability to conceive,” said Dr. Jeffrey Lysiak, Chief Scientific Officer and Co-Founder of PS Fertility. “CCF grant funding is giving us the opportunity to bring our goal of increasing the number of babies born one step closer to reality. We are grateful for VIPC’s partnership.”

 

With CCF support, PS Fertility will complete the transfer of the technology from UVA to the Charlottesville-based company’s commercial lab. Funding will also enable the startup to finalize the at-home collection test kit and begin offering the solution to patients.

 

“The CCF program has long been about fostering innovative and collaborative efforts in the Commonwealth,” said Jeanette Townsend, VIPC’s Director for Private Sector Grants. “Through VIPC’s grant to PS Fertility, we are not only supporting the commercialization activities of a Virginia startup, but also game-changing technology research and development coming out of the University of Virginia. We could not be more excited to be a part of PS Fertility’s story as they transform fertility testing and shift the industry’s 60-year status quo.”

 

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and